GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Clinical trials for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE explained in plain language.
Never miss a new study
Get alerted when new GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE trials appear
Sign up with your email to follow new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Brain-Injected cell therapy tested for deadly recurrent brain cancer
Disease control Not yet recruitingThis study is testing an experimental cell therapy called MT027 for adults with glioblastoma, a very aggressive brain cancer, that has come back or gotten worse after standard treatment. The therapy involves injecting the cells directly into the fluid-filled spaces of the brain. …
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: PHASE2 • Sponsor: T-MAXIMUM Pharmaceutical Inc • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New brain cancer drug enters human testing
Disease control Not yet recruitingThis early-stage trial is testing a new drug called LMP744 in adults whose aggressive brain cancer (glioblastoma) has returned after standard treatment. The main goal is to see if the drug can shrink or stabilize tumors and is safe for patients. Participants will receive the drug…
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC